Cardiff Oncology Inc. logo

Cardiff Oncology Inc.

CRDF | NASDAQ
Chart Builder DCF Calculator
$1.37
$0 (0.00%)
At close: Sep 21, 2026, 4:00 PM ET
$1.35
-$0.02 (-1.75%)
Pre-market: Sep 22, 2026, 9:08 AM ET

Market Data

Market Cap
$105.59M
Enterprise Value
$71.53M
Beta
1.46
Average Volume
1.28M
Shares Outstanding (Diluted)
68.4M
Shares Change YoY
2.81%
Institutional Ownership
35.99%
Exchange
NASDAQ
ISIN
US14147L1089

Price Performance

Price Change 1M
47.3%
Price Change 3M
9.6%
Price Change 6M
-20.8%
Price Change YTD
-48.5%
Price Change 1Y
-33.8%
Price Change 3Y
-14.9%
Price Change 5Y
-81.4%
1M CAGR (ann.)
38.1%
1Y CAGR (ann.)
-36.6%
5Y CAGR (ann.)
-27.3%
All-Time CAGR
-23.7%

Valuation

PE Ratio
-2.28
Forward PE
N/A
PEG Ratio
-0.04
Forward PEG
-0.42
PS Ratio
207.86
Forward PS
329.10
PB Ratio
3.98
P/FCF Ratio
-2.58
P/Adj. FCF Ratio
-2.29
P/OCF Ratio
-2.28
EV/Sales
140.80
EV/EBIT
-1.79
EV/EBITDA
-1.84
EV/FCF
-1.75
Earnings Yield
-43.8%
FCF Yield
-38.8%
Adj. FCF Yield
-43.7%

Financial Health

Net Cash
$34.52M
Total Debt
$457K
Cash & Short-Term Investments
$34.52M
Total Assets
$37.33M
Current Ratio
3.30
Quick Ratio
3.30
Debt / Equity Ratio
0.02
Debt / EBITDA
-0.01
Debt / FCF
-0.01
OCF / Debt
-89.40
Interest Coverage
0.00
Altman Z-Score
-13.80
Piotroski F-Score
2

Margins & Profitability

Gross Profit Margin
100.0%
Operating Profit Margin
-8320.1%
EBITDA Margin
-7665.2%
Net Profit Margin
-7884.1%
FCF Margin
-8054.3%
Adj. FCF Margin
-9082.9%
SBC / Revenue
1028.5%
SBC Impact (per share)
-12.8%

Returns

Return on Assets
-107.3%
Return on Equity
-103.1%
Return on Invested Capital
-156.6%
Return on Capital Employed
-159.3%
Return on Tangible Assets
-107.3%

Historical Growth (CAGR)

Revenue CAGR 3Y
7.2%
Revenue CAGR 5Y
5.2%
Revenue CAGR 10Y
3.5%
EPS CAGR 3Y
18.6%
EPS CAGR 5Y
5.2%
EPS CAGR 10Y
47.6%
FCF CAGR 3Y
-11.0%
FCF CAGR 5Y
-8.2%
FCF CAGR 10Y
-9.9%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
15
EPS Growth Next 3Y
15.6%
Revenue Growth Next 3Y
535.3%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$0.14
EPS Growth Est (next Q)
-17.6%
Revenue Est (next Q)
$81.43K
Revenue Growth Est (next Q)
-32.1%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$2
Price Target Upside
46.0%

Cash Flow

Operating Cash Flow
$-40.85M
Free Cash Flow
$-40.92M
Adj. Free Cash Flow
$-46.14M
FCF Per Share
-$0.60
OCF Per Share
-$0.60
OCF/S Ratio
-8042.1%

Income Statement

Revenue
$508K
Gross Profit
$508K
Operating Income
$-42.27M
EBITDA
$-38.94M
Net Income
$-40.05M
EPS (Diluted)
-$0.60
Revenue / Employee
$16.39K
Profit / Employee
$-1.29M
Employees
31

© 2026 bestshares.com. All rights reserved.